Long stigmatized in the United States, wider adoption of guided backcountry skiing will boost knowledge, reduce gatekeeping, and promote human-powered skiing on public lands.
Read MoreRESTON, VA—(BUSINESS WIRE, February 18, 2021)—Clarabridge, Inc., the leading provider of Customer Experience Management (CEM) solutions for the world’s top brands, experienced a record-breaking year in 2020, with 300% increase in new customers sales YoY in Q4 and growth in overall deal size driven by speech analytics.
Read MoreOver the past 40 years, the vast majority of therapeutics that entered human testing failed to make it to market. Over the past 20 years – and really accelerating over the past 5 years – new technologies and clinical development strategies emerged that made it possible to dramatically improve on those historically dismal rates. “Precision medicine” holds the promise of the right medicine for the right patient at the right time, and represents a paradigm change from the empirical medicine practiced in the past.
Read MoreAUSTIN, Texas - January 22, 2021 - Zenoss Inc., the leader in AI-driven full-stack monitoring, today announced its company highlights for 2020. Among many noteworthy accomplishments, Zenoss saw record milestones in its Zenoss Cloud offering, the industry’s first full-stack monitoring plus AIOps platform.
Zenoss Cloud revenue grew by 229% compared to 2019. The AI-powered Zenoss Cloud platform was launched in mid-2018 and has been the company's flagship product, providing immediate root-cause analysis and preventing IT disruptions in any environment — from simple infrastructures to the most complex, dynamic multicloud IT deployments.
Read MoreSAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions.
Read MoreSAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomarker in AML.
Read MoreJason Myers and his team were honored at the CBSA awards banquet last week with the Deal of the Year Award, a well-deserved honor. See video linked in the title of this article and embedded within.
Read MoreDec. 14, 2020 - 6:55 - Two Blind Brothers founders Bradford and Bryan Manning explain the idea behind their ‘Shop Blind’ challenge, which gives 100 percent of profits to the Foundation Fighting Blindness.
Read More